Open access · OA
via Europe PMC
Outcomes of Intravitreal Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration in Kazakhstan.
Suleimenov M, Kadyrgaliyev B, Kanafyanova E, Meyermanova Z, Abdullina V, Zhankalova Z, Yeshmanova A, Abdykulova A, Almukhambetova S, Kulmaganbetov M.
Vision (Basel, Switzerland) · 2026
Abstract
<h4>Background</h4>Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss among older adults. Although randomised controlled trials have demonstrated the robust efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy, real-world outcomes often differ markedly from trial findings. This study aimed to evaluate the anatomical and functional outcomes of anti-VEGF therapy in a clinical cohort of nAMD patients, including a subgroup that received adjunctive rescue photodynamic therapy (PDT) with verteporfin.<h4>Methods</h4>This single-centre, retrospective observational cohort study included 568 patients (634 eyes) with nAMD treated with intravitreal anti-VEGF injections. Bevacizumab was used in 49% of eyes, ranibizumab in 44%, and aflibercept in 7%. Best recorded visual acuity (BRVA) and central retinal thickness (CRT) measured by optical coherence tomography (OCT) were recorded at baseline and at the final documented follow-up. Eyes with eccentric fixation were excluded from BRVA analysis but were retained for CRT analysis.<h4>Results</h4>Mean patient age was 71.7 ± 8.8 years, and 67.6% of eyes were from female patients. The mean number of anti-VEGF injections was 5 ± 5.3 per eye; the mean follow-up duration was 11.5 months. Mean CRT decreased significantly from 347.3 ± 27.5 μm at baseline to 324.9 ± 28.8 μm at final follow-up (<i>p</i> < 0.001). Mean BRVA (logMAR) improved modestly from 0.98 ± 0.55 (Snellen ~20/190; ~35 ETDRS letters) to 0.93 ± 0.56 (Snellen ~20/175; ~37.5 ETDRS letters) (<i>p</i> < 0.001), with 67.9% of eyes demonstrating BRVA stability (change < 0.1 logMAR). Rescue PDT was administered in 10.3% of eyes.<h4>Conclusions</h4>In this real-world cohort, anti-VEGF therapy was associated with significant anatomical improvement, as measured by CRT reduction, while functional outcomes were characterised by visual stabilisation rather than substantial gains.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3390/vision10040082
- Canonical
- link ↗
- Fetched
- 2026-10-31 MST
Cite this
APA
M, S., B, K., E, K., Z, M., V, A., Z, Z., A, Y., A, A., S, A., & M., K. (2026). Outcomes of Intravitreal Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration in Kazakhstan. <em>Vision (Basel, Switzerland)</em>. https://doi.org/10.3390/vision10040082
Vancouver
M S, B K, E K, Z M, V A, Z Z, et al. Outcomes of Intravitreal Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration in Kazakhstan. Vision (Basel, Switzerland). 2026. doi:10.3390/vision10040082.
BibTeX
@article{suleimenov2026Outcom,
title = {Outcomes of Intravitreal Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration in Kazakhstan.},
author = {Suleimenov M and Kadyrgaliyev B and Kanafyanova E and Meyermanova Z and Abdullina V and Zhankalova Z and Yeshmanova A and Abdykulova A and Almukhambetova S and Kulmaganbetov M.},
journal = {Vision (Basel, Switzerland)},
year = {2026},
doi = {10.3390/vision10040082},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Retina (Philadelphia, Pa.) 2026
Citation only
Centenarian patients with neovascular age-related macular degeneration.
Korean journal of ophthalmology : KJO 2026
Citation only
Comparison of Aflibercept and Brolucizumab in Treatment-Naïve Neovascular Age-related Macular Degeneration with Thick Pigment Epithelial Detachments.
Ophthalmology 2019
Open access · CC-BY
Macular Atrophy in Neovascular Age-Related Macular Degeneration
Retina 2006
Citation only
INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Parc de Salut Mar 2022
Open access · US-GOV
Multicentre, Randomised, Double-blind, Parallel-group, Phase III Study to Evaluate the Genetic Polymorphism Influence in the Response to Ranibizumab and Bevacizumab Treatment in Patients With Age-Associated Macular Degeneration.
British Journal of Ophthalmology 2003
Open access · OA